Bio Spec Overview
Ignite Creation Date:
2025-12-24 @ 11:43 PM
Last Modification Date:
2025-12-24 @ 11:43 PM
Retention:
SAMPLES_WITH_DNA
Description:
Blood samples will be collected to:
* Evaluate whether mutations detected in tumor tissue using various Clinical Laboratory Improvement Amendments (CLIA)-certified next-generation sequencing assays correlate with those found in plasma tumor DNA (ptDNA).
* To evaluate changes in ptDNA from baseline to 3 months in patients with spliceosome mutations receiving immune checkpoint inhibitors (ICI)
* To evaluate changes in circulating immune cells (PBMCs) from baseline to 3 months in patients with spliceosome mutations receiving ICI
* Evaluate whether mutations detected in tumor tissue using various Clinical Laboratory Improvement Amendments (CLIA)-certified next-generation sequencing assays correlate with those found in plasma tumor DNA (ptDNA).
* To evaluate changes in ptDNA from baseline to 3 months in patients with spliceosome mutations receiving immune checkpoint inhibitors (ICI)
* To evaluate changes in circulating immune cells (PBMCs) from baseline to 3 months in patients with spliceosome mutations receiving ICI
Section:
Blood samples will be collected to:
* Evaluate whether mutations detected in tumor tissue using various Clinical Laboratory Improvement Amendments (CLIA)-certified next-generation sequencing assays correlate with those found in plasma tumor DNA (ptDNA).
* To evaluate changes in ptDNA from baseline to 3 months in patients with spliceosome mutations receiving immune checkpoint inhibitors (ICI)
* To evaluate changes in circulating immune cells (PBMCs) from baseline to 3 months in patients with spliceosome mutations receiving ICI